Direct patient access Phenomix Sciences recently launched direct patient access to its MyPhenome genetic obesity test, creating a potential channel to engage patients early with personalized obesity management solutions and upsell to clinician-supported programs.

Clinical utility Evidence from Obesity Week 2025 and DDW 2025 highlights the predictive power of the MyPhenome test and its proprietary Genetic Risk Score, suggesting opportunity to position the offering as a proven decision-support tool for physicians and payers.

Partnerships & ecosystems Existing integrations with InformedDNA and collaborations with Mayo Clinic and Hello Alpha indicate a strong partner network that can be leveraged to expand distribution, co-market to payers and health systems, and scale adoption.

Market momentum Recent launches and conference presentations signal growing interest in precision obesity medicine, with multimodal phenotyping tests (Hungry Gut, Hungry Brain, Emotional Hunger) offering multiple entry points for clinical and consumer outreach.

Growth potential With revenue in the low tens of millions and ongoing funding, Phenomix is positioned for enterprise-level collaborations with mid-to-large health systems and insurers seeking genetics-guided weight management solutions.